Summary

The monoclonal antibodies market is expected to grow at a strong CAGR of around 9% during the forecast period owing to the surge in the incidence of cancers, rising research and development activities for the development of novel monoclonal antibodies, and the development of a novel pipeline of monoclonal antibodies. Moreover, getting approvals for many new monoclonal antibodies by the respective authorities is more efficient and easy. For instance, In January 2021, the antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. Apart from this, the presence of various government and non-government organizations that aim to enhance awareness and promote research is also propelling market growth. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 million in research in 2020. In addition to this, the increasing funding from government organizations for cancer-related searches is also driving the monoclonal antibodies market.

Some of the major players operating in the market include AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Bayer AG; AstraZeneca; Sanofi; Merck & Co., Inc; and Johnson & Johnson Private Limited. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst source, the human segment held a significant share of the market in 2021”
Based on source, the market is segmented into chimeric, human, humanized, and murine. The human category held the dominant share of the market in 2021 as human monoclonal antibodies offer much more efficient modulation in effector functions and are less immunogenic in comparison to chimeric or humanized monoclonal antibodies. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human monoclonal antibodies is anticipated to grow with high CAGR in the forthcoming years.

“Amongst indication, the autoimmune diseases category to grow with high CAGR during the forecast period”
By indication, the market is categorized into oncology, autoimmune diseases, infectious diseases, inflammatory diseases, and others. Autoimmune diseases is anticipated to grow with significant CAGR during the forecast period majorly due to the increase in the prevalence of rheumatoid arthritis and a large number of ongoing clinical trials. For instance, in March 2023, Enthera Pharmaceutical initiated phase-I clinical trial evaluating Ent001 or selected autoimmune conditions. Ent001 is a monoclonal antibody (mAb) targeting the IGFBP3/TMEM219 pathway, which plays a critical role in both inflammatory bowel disease (IBD) and type 1 diabetes (T1D).

“Amongst end user, the hospital segment held a dominant share of the market in 2021”
Based on end user, the market is segmented into hospital, specialty centers, and others. The hospitals held dominant share of the market in 2021 owing to rising hospital admissions due to surge in the prevalence of arious chronic diseases like cancer, autoimmune diseases, and rheumatoid arthritis among the population. Other factors, including increasing healthcare expenditure, rising patient awareness levels, and availability of advanced hospital infrastructure in developed countries are factors expected to result in the dominance of the segment during the forecast period.

“APAC to grow with high CAGR during the forecast period”
APAC is expected to grow with the highest CAGR during the forecast period. Several factors, such as rising disposable income, a large patient pool, and rising research and development activities are driving the regional market growth. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for monoclonal antibodies. In addition to this, rising product approvals will also propel the market growth. For instance, in January 2023, the National Medical Products Administration (NMPA) of China granted approval to Shanghai Henlius Biotech’s monoclonal antibody Hansizhuang in combination with carboplatin and etoposide to manage extensive stage small cell lung cancer (ES-SCLC).

ページTOPに戻る

Table of Contents